ClinVar Miner

Submissions for variant NM_001458.5(FLNC):c.161G>A (p.Gly54Asp)

gnomAD frequency: 0.00001  dbSNP: rs1032152678
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001240614 SCV001413579 uncertain significance Myofibrillar myopathy 5; Distal myopathy with posterior leg and anterior hand involvement; Hypertrophic cardiomyopathy 26; Dilated Cardiomyopathy, Dominant 2022-07-26 criteria provided, single submitter clinical testing This sequence change replaces glycine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 54 of the FLNC protein (p.Gly54Asp). This variant is present in population databases (no rsID available, gnomAD 0.003%). This missense change has been observed in individual(s) with limb-girdle muscle weakness (PMID: 29970176). ClinVar contains an entry for this variant (Variation ID: 966028). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV002393619 SCV002703224 uncertain significance Cardiovascular phenotype 2019-06-21 criteria provided, single submitter clinical testing The p.G54D variant (also known as c.161G>A), located in coding exon 1 of the FLNC gene, results from a G to A substitution at nucleotide position 161. The glycine at codon 54 is replaced by aspartic acid, an amino acid with similar properties. This variant has been detected in conjunction with variants in other genes in an individual with limb-girdle muscle weakness (Fichna JP et al. Hum. Genomics, 2018 07;12:34). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.